Navigation Links
Carl A. Miller, PhD, Joins iDiverse's Business and Scientific Advisory Board
Date:1/11/2011

DEL MAR, Calif., Jan. 12, 2011 /PRNewswire/ -- iDiverse today announced that Dr. Carl A. Miller has joined the company's Business and Scientific Advisory Board.

"We are extremely pleased to have Dr. Miller join our team at this time," said John Burr, president and CEO of iDiverse. "Dr. Miller has over forty years of extensive, hands on experience in the commercialization of novel bio-based technologies that have greatly improved the economics of production of biofuels and biomaterials. He has been directly involved in solving some of the very difficult problems associated with the pretreatment and fermentation of biomass materials to biofuels and chemicals. We believe our technology can play a significant role here and I am looking forward to Dr. Miller's help and support."

"I believe that iDiverse's technology will play an immediate role in overcoming many of the generally accepted limitations in the production of biofuels from a wide variety of fermentation substrates. The iDiverse technologies represent breakthroughs in the conventional paradigm of biofuel production from any feedstock but its greatest impact will be realized in the biomass-to-biofuels sector," said Dr. Miller.

Dr. Miller has an expansive background ranging from the development of cost-effective biofuel production process designs to the commercialization of novel industrial enzymes. He has held positions at Novozymes, Gist-brocades (now DSM), Diversa (now Verenium), Innovase and Syngenta, and is currently the president of Enventek, a biotechnology consulting company. Dr. Miller earned his PhD in bio-organic chemistry from Clemson University and did post-doctoral work on enzyme mechanism at Syracuse University.

About iDiverse

iDiverse, Inc. is a privately-held biotechnology company dedicated to developing and commercializing genetically enhanced cell lines for use in the bioproduction of fuel ethanol, industrial enzymes, and pharmaceuticals. It also provides genetic technology for creating plants that are resistant to a wide range of biological and environmental stresses.


'/>"/>
SOURCE iDiverse, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Paul Pospisil Joins Korn/Ferry as Senior Client Partner in Biotechnology and Life Sciences Practice
2. Jack Davis, Diagnostics Industry Executive, Joins the HistoRx Board of Directors
3. Dr. Russell L. Chapman Joins Aquatic Energy as the Chairman of its Science Advisory Board
4. Dr. Michael Hanley Joins Celtaxsys as CEO
5. Edwin Rivera-Martinez, Former Chief of the FDA’s International Compliance Branch, Joins PAREXEL Consulting Strategic Compliance Team
6. Distinguished Scientist H. Mario Geysen Joins SRI International to Lead Combinatorial Sciences and Metabolic Diseases Research Programs
7. Dr. Eric Johnson Joins Transgenomic as Medical Director for Laboratory Services
8. Todd Park, Chief Technology Officer of U.S. Department of Health and Human Services, Joins Opening Keynote Line-Up at 2010 mHealth Summit
9. Heiner Dreismann, Ph.D., Former President of Roche Molecular Systems, Joins the HistoRx Board of Directors
10. Excerpta Medica Joins Adelphi Worldwide
11. Philadelphia Eagles Offensive Lineman Todd Herremans Joins SPO Medical to Endorse New SPO Wellness(TM) Product Line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... ... ... EIT Digital has launched work to develop a new Smart IOT ... to get under way for the framework, which is designed to reduce the use ... to be transferred eventually to other industries that also require efficient IoT and management ...
(Date:2/16/2017)... , Feb. 16, 2017  MDNA Life ... the development of liquid biopsy tests based on ... into an exclusive license agreement with its first ... proprietary liquid biopsy test for prostate cancer, the ... Korea . This is the first overseas ...
(Date:2/16/2017)... Feb. 16, 2017   Biostage, Inc. (Nasdaq: ... biotechnology company developing bioengineered organ implants to treat cancers ... trachea, announced today the closing on February 15, 2017 ... of common stock and warrants to purchase 20,000,000 shares ... million. The offering was priced at $0.40 per share ...
(Date:2/16/2017)... N.J. , Feb. 16, 2017  Champions Oncology, ... in the development and sale of advanced technology solutions ... oncology drugs, today announced the addition of new cohorts ... These new models will expand Champions, product line ... head and neck cancer, AML, and non-small cell lung ...
Breaking Biology Technology:
(Date:2/8/2017)... 2017 The biometrics market has reached ... of organizations, desires to better authenticate or identify ... and challenge questions), biometrics is quickly working its ... market is driven by use cases, though there ... enterprise uses cases, with consumer-facing use cases encompassing ...
(Date:2/6/2017)... , Feb. 6, 2017 According to ... are driving border authorities to continue to embrace ... there are 2143 Automated Border Control (ABC) eGates ... deployed at more than 163 ports of entry ... to 2016 achieving a combined CAGR of 37%. ...
(Date:2/2/2017)... 1, 2017  Central to its deep commitment ... worldwide, The Japan Prize Foundation today announced the ... pushed the envelope in their respective fields of ... scientists are being recognized with the 2017 Japan ... only contribute to the advancement of science and ...
Breaking Biology News(10 mins):